Efficacy and safety of ciprofloxacin XR 1000 mg once daily versus ciprofloxacin 500 mg twice daily in the treatment of complicated urinary tract infections. 2009

V Mirone, and F Fusco, and D Taglialatela, and P Verze, and C Di Vito, and T Lotti, and C Imbimbo, and
Department of Urology, University Federico II, Naples, Italy.

The aim of this trial was to compare the efficacy and safety of extended-release ciprofloxacin (CIPRO XR) versus the immediate-release formulation (CIPRO IR) in the treatment of complicated urinary tract infections (UTIs). 212 patients were randomized to CIPRO XR 1,000 mg tablet once daily or CIPROXIN IR 500 mg tablet twice daily. Treatment efficacy was evaluated by bacteriological outcome. Safety was measured by recording adverse events. The rate of bacteriological eradication was 83% in the CIPRO XR group and 75% in the CIPRO IR. the overall incidence of adverse events reported was higher in the CIPRO IR group. The authors conclude that CIPRO XR is a safe and effective treatment for complicated UTIs. Although the limited data available do not consent to support a statistically superior efficacy or safety compared to CIPRO IR, a trend in favor of CIPRO XR is clearly evident in all efficacy and safety variables. CIPRO XR is associated with reduced frequencies of drug-related adverse events compared to CIPRO IR.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002939 Ciprofloxacin A broad-spectrum antimicrobial carboxyfluoroquinoline. Bay-09867,Ciprinol,Cipro,Ciprofloxacin Hydrochloride,Ciprofloxacin Hydrochloride Anhydrous,Ciprofloxacin Monohydrochloride Monohydrate,Anhydrous, Ciprofloxacin Hydrochloride,Bay 09867,Bay09867,Hydrochloride Anhydrous, Ciprofloxacin,Hydrochloride, Ciprofloxacin,Monohydrate, Ciprofloxacin Monohydrochloride,Monohydrochloride Monohydrate, Ciprofloxacin
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000890 Anti-Infective Agents Substances that prevent infectious agents or organisms from spreading or kill infectious agents in order to prevent the spread of infection. Anti-Infective Agent,Anti-Microbial Agent,Antimicrobial Agent,Microbicide,Microbicides,Anti-Microbial Agents,Antiinfective Agents,Antimicrobial Agents,Agent, Anti-Infective,Agent, Anti-Microbial,Agent, Antimicrobial,Agents, Anti-Infective,Agents, Anti-Microbial,Agents, Antiinfective,Agents, Antimicrobial,Anti Infective Agent,Anti Infective Agents,Anti Microbial Agent,Anti Microbial Agents
D014552 Urinary Tract Infections Inflammatory responses of the epithelium of the URINARY TRACT to microbial invasions. They are often bacterial infections with associated BACTERIURIA and PYURIA. Infection, Urinary Tract,Infections, Urinary Tract,Tract Infection, Urinary,Tract Infections, Urinary,Urinary Tract Infection

Related Publications

V Mirone, and F Fusco, and D Taglialatela, and P Verze, and C Di Vito, and T Lotti, and C Imbimbo, and
October 1997, The Journal of urology,
V Mirone, and F Fusco, and D Taglialatela, and P Verze, and C Di Vito, and T Lotti, and C Imbimbo, and
May 2000, European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology,
V Mirone, and F Fusco, and D Taglialatela, and P Verze, and C Di Vito, and T Lotti, and C Imbimbo, and
February 1999, International journal of antimicrobial agents,
V Mirone, and F Fusco, and D Taglialatela, and P Verze, and C Di Vito, and T Lotti, and C Imbimbo, and
March 2004, International journal of antimicrobial agents,
V Mirone, and F Fusco, and D Taglialatela, and P Verze, and C Di Vito, and T Lotti, and C Imbimbo, and
April 1997, The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases,
V Mirone, and F Fusco, and D Taglialatela, and P Verze, and C Di Vito, and T Lotti, and C Imbimbo, and
April 1998, Journal of chemotherapy (Florence, Italy),
V Mirone, and F Fusco, and D Taglialatela, and P Verze, and C Di Vito, and T Lotti, and C Imbimbo, and
June 1999, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi,
V Mirone, and F Fusco, and D Taglialatela, and P Verze, and C Di Vito, and T Lotti, and C Imbimbo, and
September 1982, The Journal of antimicrobial chemotherapy,
V Mirone, and F Fusco, and D Taglialatela, and P Verze, and C Di Vito, and T Lotti, and C Imbimbo, and
January 1993, Infection,
Copied contents to your clipboard!